How Bad Policy and Bad Evidence Harm People with Cancer
Narrado por: Vinayak K. Prasad
Duración: 7 horas y 23 mins

Este título forma parte de nuestro catálogo extendido. Comienza tu prueba gratis y obténlo por un precio exclusivo para suscriptores de 9,99€ o menos.

Después de los 30 días, 9,99 €/mes. Cancela cuando quieras
Escucha sin límites más de 90.000 audiolibros, podcasts originales y contenido exclusivo. Además, nuevos títulos cada semana.
Accede a títulos adicionales de nuestro catálogo extendido, con un precio de compra especial para suscriptores de 9,99€ o menos
Sin compromiso. Cancela gratis en cualquier momento y conserva los títulos que hayas comprado.
Compra ahora por 17,99 €

Compra ahora por 17,99 €

Paga utilizando la tarjeta terminada en
Al confirmar tu compra, aceptas las Condiciones de Uso de Audible y nos autorizas a realizar el cobro mediante los métodos de pago por ti designados. Por favor revisa nuestra Política de Privacidad, Política de cookies y Aviso sobre anuncios basados en intereses

Resumen del editor

Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel, but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. 

In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad discusses about the many sobering examples of how patients are too often failed by cancer policy and by how oncology is practiced. 

Throughout this audiobook, Prasad illuminates deceptive practices, which:

  • Promote novel cancer therapies long before credible data are available to support such treatment
  • Exaggerate the potential benefits of new therapies, many of which cost thousands and in some cases hundreds of thousands of dollars

Prasad then critiques the financial conflicts of interest that pervade the oncology field, the pharmaceutical industry, and the US Food and Drug administration. This is a book about how the actions of human beings - our policies, our standards of evidence, and our drug regulation - incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices. 

He takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price.

Ultimately, Prasad says:

  • More cancer clinical trials should measure outcomes that actually matter to people with cancer.
  • Patients on those trials should look more like actual global citizens.
  • We need drug regulators to raise, not perpetually lower, the bar for approval.
  • We need unbiased patient advocates and experts.

This well-designed, opinionated, and engaging audiobook explains what we can do differently to make serious and sustained progress against cancer and how we can avoid repeating the policy and practice mistakes of the past.

PLEASE NOTE: When you purchase this title, the accompanying PDF will be available in your Audible Library along with the audio.

©2020 Vinayak K. Prasad (P)2020 Vinayak K. Prasad

Lo que los oyentes dicen sobre Malignant

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.